Skip to content

Study · Animal study (in vivo) · mouse · 2024

1 result

Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza.

West AC, Harpur CM, Le Page MA, Lam M, Hodges C, Ely LK, Gearing AJ, Tate MD

The Journal of infectious diseases1 Aug 2024Cited by 6 (Europe PMC)

PMID38060822 (opens in a new tab)PMCIDPMC11326819 (opens in a new tab)DOI10.1093/infdis/jiad566 (opens in a new tab)PepBankPUB-38060822
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

BackgroundExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT8881 is a synthetic 16-amino acid cyclic peptide form of a naturally occurring C-terminal fragment of human growth hormone with therapeutic efficacy against influenza. Shorter linear peptides are typically easier to manufacture and formulate for delivery than larger cyclic peptides. A 6-amino acid linear peptide fragment of LAT8881, LAT9997, was investigated as a potential influenza therapy.MethodsLAT9997 was evaluated for its potential to limit disease in a preclinical mouse model of severe influenza infection.ResultsIntranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes. Initiating LAT9997 treatment at the onset of severe disease also significantly improved disease severity. Greater disease resistance in LAT9997-treated mice correlated with reduced lung immunopathology, damage markers, vascular leak, and epithelial cell death. Treatment reduced viral loads, cytokines, and neutrophil infiltration in the airways yet maintained protective alveolar macrophages in a dose-dependent manner. Sequential trimming of N- and C-terminal amino acids from LAT9997 revealed a structure-activity relationship.ConclusionsThese findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.SummaryExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT9997 is a linear peptide fragment derived from human growth hormone. This study provides preclinical evidence that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with severe influenza infection, intranasal LAT8881 started from day 1 after infection significantly improved survival outcomes.

    In plain wordsIn mice with severe flu, LAT8881 given into the nose from day 1 after infection improved survival.

    Peptide
    AOD-9604
    Outcome
    IncreaseSurvival in severe influenza
    Study

    mousen: not reported in source

    severe influenza infection
    Outcome group
    Mortality · Infection
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    Intranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.